2079878-75-2

Basic information

• Product Name: 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one
• CAS NO: 2079878-75-2
• Molecular Weight: 253.685
• Mol File: 2079878-75-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one(2079878-75-2)
• EPA Substance Registry System: 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one(2079878-75-2)

Safety Data

• Hazardous Substances Data: 2079878-75-2(Hazardous Substances Data)

Usage

General Description

2-(2-chlorophenyl)-2-nitrocyclohexan-1-one is a chemical compound with the molecular formula C12H11ClNO3. It is a nitro compound with a cyclohexanone ring and a chlorophenyl group attached to the second carbon of the ring. 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It can also be used as a building block for the production of agrochemicals and other specialty chemicals. It is important to handle this compound with care as it may be toxic and potentially harmful if not used properly.

Upstream product

• 108-94-1 cyclohexanone 
• 4883-67-4 2-nitrocyclohexanone 
• 286-20-4 cyclohexane-1,2-epoxide 
• 694-80-4 2-bromo-1-chlorobenzene 
• 91393-49-6 2-amino-2-(2-chlorophenyl)cyclohexan-1-one 

Downstream Products

• 35211-10-0 norketamine 
• 6740-88-1 ketamine 

Relevant articles and documents

NMDA receptor antagonist and use thereof

The present invention relates to an NMDA receptor antagonist and use thereof. The NMDA receptor antagonist is a compound as shown in the formula I, and pharmaceutically acceptable salts, enantiomers, diastereoisomers, tautomers, solvates, isotope substitutes, polymorphic substances, prodrugs or metabolites thereof, and in the formula, ring A, ring B and R2 are as described in the specification. The invention also provides pharmaceutical compositions containing the compounds, and applications of the compounds in preparation of drugs for treating or preventing NMDA receptor mediated diseases.

Intermediate compound for synthesizing ketamine and method for synthesizing ketamine

The invention discloses an intermediate compound for synthesizing ketamine, having a chemical structural formula shown in the specification. The intermediate compound is prepared by: (i) reacting o-chlorobromobenzene and lithium alkylide to obtain lithium o-chlorophenyl; (ii) reacting the lithium o-chlorophenyl and cyclohexene oxide under the action of Lewis acid. The intermediate compound may be oxidized, nitrified, nitro-reduced and then amino-methylated to produce ketamine. Compared with existing synthetic methods of ketamine, the method of the invention has simple route, low cost and good operation convenience.